NewAmsterdam Pharma (NASDAQ:NAMS) Stake Lifted by Frazier Life Sciences Management L.P.

Frazier Life Sciences Management L.P. raised its holdings in shares of NewAmsterdam Pharma (NASDAQ:NAMS) by 5.1% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 12,855,194 shares of the company’s stock after buying an additional 628,251 shares during the quarter. NewAmsterdam Pharma comprises about 8.6% of Frazier Life Sciences Management L.P.’s portfolio, making the stock its 2nd biggest holding. Frazier Life Sciences Management L.P. owned approximately 14.28% of NewAmsterdam Pharma worth $213,396,000 at the end of the most recent quarter.

A number of other hedge funds have also modified their holdings of NAMS. Banque Cantonale Vaudoise purchased a new position in NewAmsterdam Pharma during the second quarter worth approximately $38,000. Quarry LP increased its stake in shares of NewAmsterdam Pharma by 2,469.2% in the 3rd quarter. Quarry LP now owns 6,500 shares of the company’s stock worth $108,000 after acquiring an additional 6,247 shares during the last quarter. Barclays PLC raised its holdings in shares of NewAmsterdam Pharma by 1,813.4% during the 3rd quarter. Barclays PLC now owns 7,596 shares of the company’s stock worth $126,000 after acquiring an additional 7,199 shares during the period. Bellevue Group AG acquired a new position in shares of NewAmsterdam Pharma during the 3rd quarter valued at about $128,000. Finally, XTX Topco Ltd purchased a new stake in shares of NewAmsterdam Pharma in the third quarter valued at about $187,000. 89.89% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on the stock. Needham & Company LLC reaffirmed a “buy” rating and set a $36.00 target price on shares of NewAmsterdam Pharma in a research note on Thursday, December 5th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $31.00 price target on shares of NewAmsterdam Pharma in a research report on Thursday, September 5th. Finally, Piper Sandler reiterated an “overweight” rating and issued a $37.00 price objective on shares of NewAmsterdam Pharma in a research report on Monday, September 23rd. Six research analysts have rated the stock with a buy rating, According to MarketBeat, the stock has an average rating of “Buy” and a consensus price target of $33.80.

Insider Activity at NewAmsterdam Pharma

In related news, CAO Louise Frederika Kooij sold 45,000 shares of the stock in a transaction dated Tuesday, October 1st. The stock was sold at an average price of $15.72, for a total transaction of $707,400.00. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, major shareholder Nap B.V. Forgrowth sold 33,273 shares of the firm’s stock in a transaction dated Monday, November 18th. The shares were sold at an average price of $25.08, for a total value of $834,486.84. Following the transaction, the insider now owns 11,778,760 shares of the company’s stock, valued at $295,411,300.80. This trade represents a 0.28 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 86,803 shares of company stock worth $1,755,307. Insiders own 19.50% of the company’s stock.

NewAmsterdam Pharma Trading Up 0.9 %

Shares of NAMS opened at $18.52 on Tuesday. The firm has a 50-day simple moving average of $19.87 and a two-hundred day simple moving average of $18.53. NewAmsterdam Pharma has a 1-year low of $9.39 and a 1-year high of $26.35.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.